Hyperfine Stock Earnings Reports

Hyperfine reported a strong start to 2026 with Q1 revenue of $3.9M (+83% YoY) driven by 10 unit sales (vs. 6 in prior year), its second‑highest quarter. Gross margin expanded to ~51% (third consecutive quarter >50%) and gross profit was $2.0M. Operating discipline and a smaller R&D base reduced cash burn (net cash burn ex‑financing of $8.8M in Q1) and net loss narrowed to $8.6M ($0.09/share). Key commercial and regulatory milestones include CE and UKCA clearance for the next‑generation subsystem and Optive AI, launch of advanced DWI Optive AI, and >50% enrollment in the contrast PMR study (supporting a potential 2026 submission to add contrast indication). Commercial traction is broadening across three verticals—hospitals/IDNs (growing multi‑site pipeline, longer sales cycles), neurology offices (larger practices adopting first), and international (Europe launch targeted Q3 after translations; first systems live in India). The company reiterated full‑year 2026 guidance: revenue $20–22M (midpoint ~55% growth), gross margin 50–55% (expected to improve in H2), and total cash burn $26–28M (midpoint ~10% YoY decline). Cash and equivalents were $40.8M as of 3/31/2026, including an initial $15M tranche of up to $40M facility; management expects runway into 2028 (exclusive of additional tranches). Management highlighted ongoing innovation (software upgrades planned by year‑end), pilots for new sites of care (OR/angio suite, mobile/community screening), and the potential commercial upside if a contrast indication is achieved.